

Contact: Heather Koshinsky Location: Hercules, CA Email: <u>ceo@investigen.com</u> Tel: 510.964.9700

Website: http://www.investigen.com


Company Profile

Industry Sector: Molecular Diagnostics

Company Overview: Investigen, Inc. is part of the revolution in point of care (POC) nucleic acid detection by developing a proprietary smartDNATM Molecular Diagnostic platform. While smartDNA can be used in laboratories, its simplicity should make it uniquely able to serve in diagnostic tests that can be used away from a central lab (in peripheral labs, at the POC or at the point of sample collection (POS).

Target Market(s):

TB – developing world Rapid isothermal NA diagnostics



Management

Leadership:

Heather Koshinsky, CEO-Co Founder Didier Perez, CFO & Bus. Dev. Bill Rutter, COB, co founder of Chiron Mickey Urdea, SAB, cofounder of Tethys

Scientific Advisory Board:

ASSAY CHEMISTRY (1) Bruce Armitage, Carnegie Mellon (2) Peter Nielsen, U. Copenhagen, (3) Jerzy Paczkowski, Bydgoszcz Univ,, Poland

BIOINFORMATICS (1) Yuriy Fofanov, UniveHouston, (2) Catherine Putonti, Loyola Univ. Chicago

ENGINEERING, Alex Izmailov, ASC, Canada TB (1) Abdulrahman A. Alrajhi, King Feisal Hospital, Saudi Arabia, (2) Niaz Banaiee, Stanford (3) EllenJo Baron, Stanford (4) Budiman Bela, Univ Indonesia, Jakarta (5) Cynthia Daniel, Cbanatuan City, Philippines, (6) Omoniyi Fadare, Nigeria National TB & Leprosy Control Program, (7) Philip Hopewell, UCSF, (8) Midori Kato-Maeda UCSF, (9) Laurence Huang, UCSF & Mulago Hospital, Uganda, (10) John Peabody, IGH, (11) Nadia Wiweko

National Institutes of Health

Larta

National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Key Value Drivers

Technology: Investigen's smartDNA is a simple, rapid, novel colorimetric NA detection technology. smartDNA is performed rapidly at room temperature and uses inexpensive, stable reagents. Investigen has discovered that a subset of cyanine-based dyes undergo a light-dependent chemical reaction when they bind to a PNA-NA hybrid. Under the correct conditions, this dye-PNA-NA complex becomes an artificial catalytic site that causes the conversion of the dye to a colorless form and ultimately renders the solution colorless. A prototype assay and for detection of TB have been developed.

Competitive Advantage:

- No temperature control
- No enzyme
- No expensive equipment
- Rapid, Easy
- Stable reagents

Plan & Strategy: Seeking a licensing partner.

Product Pipeline

BUSINESS	
✓ Q4 2007 – I	
Q2 2008 – Nego	
✓ Q2 2008 – I	
Q3 2008 – Nego	
SCIENCE	
🖌 Q1 2008 – F	
✓ Q2 2008 – I	
✓ Q2 2008 – F	
Q3 2008 – Deve	
Q1 2009 – Proto	